Peak Processing Limited (PKP) Fair Value & Analysis
Healthcare · AU · Market cap A$17.4M
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price +13.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0150 – A$0.0300 · fair‑value band A$0.0200 – A$0.0300 · the A$0.0170 price screens below the A$0.0300 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Peak Processing Limited (PKP) currently trades at A$0.0170, while our model-based Fair Value estimate is A$0.0300 — implying the stock looks roughly 76.5% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Peak Processing Limited generated revenue of A$15.5M at a net margin of -53.9%. Fundamentals as of Jun 23, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
Peak Processing Limited, together with its subsidiaries, manufactures, distributes, and sells recreational cannabis products in Canada and the United States. The company offers cannabis products, including beverages, hydrocarbon extracts, oils, vapes, oils, topicals, powders, infused flowers, and edibles. It also provides market insights and analysis, product development, manufacturing, commercialization, distribution, and product rework services. The company sells its products through retail stores. The company was formerly known as Althea Group Holdings Limited and change its name to Peak Processing Limited in November 2025. Peak Processing Limited was founded in 2016 and is based in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Peak Processing Limited reported revenue of A$15.6M in FY2025 versus A$11.1M in FY2021, a compound +8.9%/yr. Reported net income was −A$8.3M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,747 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Peak Processing Limited (PKP) undervalued?
What is the fair value of PKP?
What is the quality score of PKP?
What is the revenue of Peak Processing Limited (PKP)?
What is the net profit margin of PKP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.